SGLT2 Inhibitors Improve Cardiovascular Outcomes Across Groups - Medscape
A comprehensive meta-analysis finds cardiovascular improvement across age, sex, and race/ethnicity for high-risk individuals with type 2 diabetes and other CVD risk factors.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors show "remarkable consistency of class benefit" for improving cardiovascular outcomes in high-risk people across age, sex, and race/ethnicity categori… [+4781 chars]
Read More
Other Stories in Health
- Bias Awareness helps bridge the gap between human and AI healthcare
- Short course chemotherapy boosts survival rates in cervical cancer patients
- More than 700,000 Australians live with acquired brain injury
- Team Member Introduction Order
- Baldwin Wallace ABSN Fall 2025
- Dallas College Spring 2025
- Oral health strategies for healthy aging: A call to action
- New research explores hydrogen sulfide as treatment for obesity
- Surge in malaria cases linked to aircraft-transported mosquitoes
.png)
